Results 121 to 130 of about 576,009 (340)

Association of obstructive sleep apnea syndrome with the signs of non-alcoholic fatty liver disease and calculated glomerular filtration rate in metabolic syndrome

Терапевтический архив, 2010
Aim: to assess a relationship between obstructive sleep apnea syndrome (OSAS) and the signs of non-alcoholic fatty liver disease (NAFLD) in patients with metabolic syndrome (MS). Material and methods.
M M Severova, V V Fomin, M V Lebedeva, Yu D Sorokin, E A Saginova, E G Minakova, M G Gallyamov, N A Mukhin   +7 more
doaj  

Country Profile on Disability: Republic of Uzbekistan [PDF]

, 2002
[Excerpt] The Law on Social Security of Disabled People in the Republic of Uzbekistan, Article 1 defines a person with disability as one who is in need of aid because he/she has physical or mental problems. Daily activities such as moving, orientation,
Japan International Cooperation Agency
core   +1 more source

Environmentally induced, occupational diseases with emphasis on chronic kidney disease of multifactorial origin affecting tropical countries [PDF]

, 2016
Shehani A. Wimalawansa, Sunil J. Wimalawansa   +1 more
openalex   +1 more source

The Effect of Smoking on Work-Related Diseases and the Consequences of Exposure to Occupational Harmful Agents at Workplace [PDF]

, 2023
Fatemeh Ramrudi Nasab, Mahdieh Rastimehr, Masoud Dougounchi   +2 more
openalex   +1 more source

Exposure to occupational inhalants and the risk of developing rheumatoid arthritis: A systematic review and meta‐analysis

Arthritis &Rheumatology, Accepted Article.
Objective: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint pain, swelling, and stiffness. While smoking is a well‐established risk factor for RA, the role of occupational inhalants in RA development is less well recognized.
Qianwen Liu, Xin Song, Emily Mauro, Yuan Jiang, Klementy Shchetynsky, PLars Klareskog, Lars Alfredsson, Xia Jiang   +7 more
wiley   +1 more source

Actively carrying out prevention and control of occupational injuries, and promoting comprehensive protection of workers' health

环境与职业医学
During the career life cycle, workers may face various health problems such as occupational injuries, occupational diseases, and work-related diseases.
Xiaojun ZHU, Yishuo GU, Jingguang FAN
doaj   +1 more source

Organisational downsizing, sickness absence, and mortality: 10-town prospective cohort study [PDF]

, 2004
Objective To examine whether downsizing, the reduction of personnel in organisations, is a predictor of increased sickness absence and mortality among employees.Design Prospective cohort study over 7.5 years of employees grouped into categories on the ...
Ferrie, JE, Kivimaki, M, Linna, A, Pentti, J, Vahtera, J, Virtanen, M, Virtanen, P   +6 more
core  

Serious Infections in Offspring Exposed to Tumor Necrosis Factor Inhibitors During Pregnancy: Comparison of Timing During Pregnancy and Placental Transfer Ability

Arthritis &Rheumatology, EarlyView.
Objective We evaluated serious infection risk in offspring exposed to tumor necrosis factor inhibitors (TNFi) in utero, separated by TNFi timing and placental transfer ability. Methods Using MarketScan (2011–2021), we identified offspring born to mothers with chronic inflammatory diseases.
Leah K. Flatman, Sasha Bernatsky, Yvan St‐Pierre, Marie‐Eve Beauchamp, Isabelle Malhamé, Anick Bérard, Évelyne Vinet   +6 more
wiley   +1 more source

Trends in Occupational Diseases in Italian Industry and Services From 2006 To 2019. [PDF]

Med Lav, 2023
Larese Filon F, Spadola O, Colosio C, Van Der Molen H.   +3 more
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study

Arthritis &Rheumatology, Accepted Article.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, The TULIP‐SC investigators   +12 more
wiley   +1 more source